Wedbush Sticks to Its Hold Rating for Omeros (OMER)

In a report released today, Liana Moussatos from Wedbush reiterated a Hold rating on Omeros (OMERResearch Report), with a price target of $18.00. The company’s shares closed last Monday at $15.21.

According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -3.8% and a 41.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.

Currently, the analyst consensus on Omeros is a Moderate Buy with an average price target of $25.67.

See today’s analyst top recommended stocks >>

The company has a one-year high of $20.92 and a one-year low of $10.30. Currently, Omeros has an average volume of 399.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.